Gilead reports positive OS results for Trodelvy in TROPiCS-02 trial
Gilead Sciences has reported positive overall survival (OS) results from the TROPiCS-02 phase 3 clinical trial of Trodelvy (sacituzumab govitecan-hziy) in patients having HR+/HER2- metastatic breast cancer. The